Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma…
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s…
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi SAN…